Researchers at Stanford and Berkeley Lab’s Molecular Foundry have developed virus-killing molecules called peptoids. The technology could make possible an emerging category of antiviral drugs that could treat everything from herpes and COVID-19 to the common cold.
The 2021 Virtual ACSM Basic Science World Congress focuses on regenerative medicine. Chaired by Marcas M. Bamman, Ph.D., FACSM, from the University of Alabama at Birmingham, this world congress brings together researchers to discuss cutting-edge science in this rapidly developing field.
A study led by Case Western Reserve University researchers found that patients with dementia were at a significantly increased risk for COVID-19—and the risk was higher still for African Americans with dementia.
Working with their colleagues at the University of Pennsylvania, researchers at the University of Kentucky have found that they can differentiate between subtypes of dementia inducing brain disease. “For the first time we created criteria that could differentiate between frontotemporal dementia (FTD) and a common Alzheimer’s ‘mimic’ called LATE disease,” explained Dr. Peter Nelson of the Sanders-Brown Center on Aging at the University of Kentucky.
Neuroscientist at the University at Albany will research how different types of memories are formed and stored at different times of the day, and how they are modified by different types of cells
University of Miami Miller School of Medicine investigators play a pivotal role in a consortium of Florida institutions just awarded a $15 million grant to collaborate on Alzheimer’s disease research. The five-year National Institutes of Health/National Institute on Aging grant brings together top Florida researchers to focus on better understanding how to diagnose, treat, prevent, and potentially cure Alzheimer’s in diverse populations.
The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form of dementia.
A Georgetown University Medical Center clinical trial investigating the cancer drug nilotinib in people with Alzheimer’s disease finds that it is safe and well-tolerated, and researchers say the drug should be tested in a larger study to further determine its safety and efficacy as a potential disease-modifying strategy.
Amyloid is a key feature of Alzheimer’s disease, but the accumulation of these sticky proteins may not be the only risk factor for developing Alzheimer’s disease, according to a new study published this week. Other, modifiable risk factors, such as the amount of fats in our blood and how efficiently our bodies generate energy could also play important roles.
Research found that those who are optimistic contribute to the health of their partners, staving off the risk factors leading to Alzheimer’s disease, dementia and cognitive decline as they grow old together.
When it comes to certain parts of the brain, bigger doesn’t necessarily equate to better memory. According to a new study led by Michigan State University, a larger hippocampus, a curved, seahorse-shaped structure embedded deep in the brain, does not always reliably predict learning and memory abilities in older adults.
Preclinical research has revealed a key missing piece of the Alzheimer’s disease puzzle. That allowed proof-of-concept experiments — using an existing drug — that dramatically reduced Alzheimer’s pathology and symptoms in mouse models, potentially offering an immediate treatment for this disease.
Houston Methodist scientists identified a protein found in ovarian cancer that may contribute to declining brain function and Alzheimer’s disease, by combining computational methods and lab research.
A team from the Beaumont Research Institute believes low-dose radiation might be a promising treatment for Alzheimer’s disease. The researchers are now seeking patients with Alzheimer’s disease for the study.
A paper published today in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, researchers at Beth Israel Deaconess Medical Center (BIDMC) shed new light on a genetic risk factor for Alzheimer’s disease that may indirectly influence patients’ risk of postoperative delirium.
A gene called apolipoprotein E (APOE), long implicated in Alzheimer’s disease, has two variants that act differently among Caribbean Hispanics depending on the ancestral origin, according to a study published in Alzheimer’s and Dementia, the journal of the Alzheimer’s Association.
The advisory council is made up of federal and non-federal members who serve overlapping four-year terms. As a new member, Ordóñez brings the perspectives of Hispanic and Latino Americans and providers of long-term services and support.
A UCLA-led study finds that, with the use of MRI scans, it is possible to distinguish between memory loss caused by Alzheimer’s disease and traumatic brain injury.
Older people who experienced more hospitalizations and also had more Alzheimer’s pathology in their brain experienced the fastest rates of cognitive decline, according to study results published in the October 15 online issue of the Annals of Neurology.
Everybody knows sleep is good for your body. It may be good for your mind, too.
That’s what scientists at Wake Forest School of Medicine will attempt to determine thanks to a $5.3 million grant from the National Institute on Aging, part of the National Institutes of Health.
Irvine, Calif., Aug. 21, 2019 — Scientists from the University of California, Irvine School of Biological Sciences have discovered how to forestall Alzheimer’s disease in a laboratory setting, a finding that could one day help in devising targeted drugs that prevent it. The researchers found that by removing brain immune cells known as microglia from rodent models of Alzheimer’s disease, beta-amyloid plaques – the hallmark pathology of AD – never formed.